First generation tau-radiotracers have already provided topographic distribution and quantitative estimates of tau pathology in AD and non-AD tauopathies closely matching the known patterns in autopsy.16, , , , –21 However, relevant amounts of the signal of first generation tau-PET ligands prove to be non-specific22,23 which accelerated the development of next-generation tau PET ligands with reduced off-target binding.14,24, , –27. This evidence concerns the gene MAPT and Alzheimer disease.